Shares of VolitionRx Limited (NYSEAMERICAN:VNRX – Get Free Report) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.86 and traded as low as $1.24. VolitionRx shares last traded at $1.25, with a volume of 47,276 shares changing hands.
Wall Street Analysts Forecast Growth
VNRX has been the topic of several analyst reports. Cantor Fitzgerald reduced their price target on shares of VolitionRx from $3.00 to $2.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 16th. StockNews.com upgraded shares of VolitionRx to a “sell” rating in a report on Sunday, July 30th.
VolitionRx Stock Performance
VolitionRx (NYSEAMERICAN:VNRX – Get Free Report) last issued its earnings results on Monday, August 14th. The medical research company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.29 million. VolitionRx had a negative return on equity of 15,493.47% and a negative net margin of 9,158.31%. Sell-side analysts predict that VolitionRx Limited will post -0.5 earnings per share for the current year.
Institutional Investors Weigh In On VolitionRx
Institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning purchased a new stake in VolitionRx in the fourth quarter valued at $32,000. Dfpg Investments LLC purchased a new stake in shares of VolitionRx in the second quarter valued at about $38,000. Jane Street Group LLC purchased a new stake in shares of VolitionRx in the first quarter valued at about $50,000. Cubist Systematic Strategies LLC purchased a new stake in shares of VolitionRx in the first quarter valued at about $58,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of VolitionRx in the first quarter valued at about $72,000. 10.14% of the stock is owned by hedge funds and other institutional investors.
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.
- Five stocks we like better than VolitionRx
- How to Calculate Stock Profit
- Why Ambarella’s 20% Decline is a Strong Signal for New Investment
- What Does the Consumer Price Index Measure?
- Why Analysts Love These 2 Car Sales Platforms, And Avoid Dealers
- Investing in Agriculture 101: How to Invest in Agriculture
- A Significant Reversal is in Sight for These 5 Med Tech Companies
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.